We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Open Biosystems' Open Access RNAi Program Continues to Gain Momentum Worldwide
News

Open Biosystems' Open Access RNAi Program Continues to Gain Momentum Worldwide

Open Biosystems' Open Access RNAi Program Continues to Gain Momentum Worldwide
News

Open Biosystems' Open Access RNAi Program Continues to Gain Momentum Worldwide

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Open Biosystems' Open Access RNAi Program Continues to Gain Momentum Worldwide"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Open Biosystems, Inc. has announced that University College London (UCL), U.K., and the Hospital for Sick Kids, Toronto, Canada, have recently purchased access to Open Biosystems' shRNAmir technologies for RNAi by joining the Open Access RNAi™ Program.

The Open Access Program supports Open Biosystems' vision of supporting basic and medical research and reinforces its commitment to expanding access to research reagents for the life sciences community.

Both institutions purchased access to Open Biosystems' lentiviral shRNAmir libraries developed in collaboration with Drs Greg Hannon and Steve Elledge and exclusively distributed through Open Biosystems.

"Functional genomics is playing an ever important role in deciphering the roles of specific genes in cancer and developmental biology, as well as in neuro-sciences, infectious diseases and immunity. Open Biosystems' Open Access RNAi program helped foster this collaboration between the UCL Cancer Institute (hosting the new RNAi facility), UCL Institutes for Child Health

and Neurology, and Division of Infection and Immunity, enabling us to provide world-class scientists in central London access to the latest shRNA libraries for focused functional screens, as well as stable knock-down experiments for pre-clinical models." said Dr. Chris Boshoff, Director, UCL Cancer Institute.

"Gene silencing using RNAi is gaining popularity around the world as researchers realize and witness its value both for understanding gene function and for the treatment of disease," said Brian Pollock, Chief Executive Officer at Open Biosystems. "By providing broad availability of RNAi resources across whole institutions, the Open Access Program creates a collaboration that encourages and supports scientific advancements."

Open Biosystems' portfolio of RNAi resources include shRNAmir lentiviral and retroviral libraries targeting the entire human and mouse genomes, the RNAi Consortium human and mouse lentiviral shRNA libraries as well as RNAi collections targeting Drosophila, C. elegans and Arabidopsis Thaliana. Participation in the Open Access RNAi program provides researchers the most complete and flexible access to their choice of these rapidly evolving RNAi technologies.

The Open Biosystems Open Access RNAi Program gives entire academic systems, including multiple campuses, access to the company's advanced shRNA libraries, priority technical support, and continued access to all extensions of existing libraries as well as library upgrades. In this manner, Open Biosystems supports academic research without imposing heavy financial burdens on individual labs. The program is customizable and can be tailored to fit the diverse needs of research institutions worldwide.

Advertisement